Brain Imaging Study of New Antipsychotic Medicine
Part of Mental health clinical trials.
This study uses special PET brain scans to see how a new experimental antipsychotic medication (SIPI6398) attaches to dopamine receptors in the brain. Researchers want to understand how the medication works and if it might help people with schizophrenia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old
- Have a healthy weight (BMI 19–32 for healthy volunteers; 19–35 for those with schizophrenia)
- Be willing to stay in the hospital for several days during the study
- Be fluent in English (written and spoken) to provide informed consent
- Not be pregnant, nursing, or planning pregnancy in the next 90 days
- Have no serious medical or psychiatric conditions that would make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
This study tests whether using brain scans and genetic tests can help choose the best treatment for people early in their schizophrenia. It will check if these biomarkers can predict who will respond better to medication.
This study tests an experimental drug (NBI-1117568) for people with schizophrenia who are currently in the hospital due to worsening symptoms. Participants stop their current antipsychotic and take the study drug to see if it can help control symptoms.
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
This trial tests a new combination pill (xanomeline/trospium) for people who started treatment for schizophrenia in the last 5 years, to see if it helps better than their current medicine. You would stop your current antipsychotic and switch to this study drug under close doctor supervision.
Hear when a new Schizophrenia Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.